Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Prognostic and comparative performance of cardiovascular risk markers in patients with type 2 diabetes: 2型糖尿病患者心血管危险标志物的预后和比较表现

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Prospective study of gestational diabetes and fatty liver scores 9 to 16 years after pregnancy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prediction of Excessive Weight Gain in Insulin Treated Patients with Type 2 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Striated muscle fiber size, composition, and capillary density in diabetes in relation to neuropathy and muscle strength

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Effect of liraglutide on expression of inflammatory genes in type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Neprilysin inhibition increases glucagon levels in humans and mice with potential effects on amino acid metabolism

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Background: Diagnostic tests including echocardiography, albuminuria, electrocardiogram (ECG), high-sensitivity troponin I (hs-TnI), and N-terminal prohormone brain natriuretic peptide (NT-proBNP) have been suggested as cardiovascular (CV) risk predictors in type 2 diabetes. We studied the separate and combined prognostic yield of these risk markers. Methods: In all, 1030 patients with type 2 diabetes were recruited from specialized clinics in this prospective cohort study. Full echocardiographic evaluation was feasible in 886 patients in sinus rhythm with adequate image quality. ECG was performed in 998 patients. Albuminuria was measured in 1009 and NT-proBNP/hs-TnI in 933 patients. The end point was a composite of CV events. Results: The median follow-up was 4.7 years (interquartile range: 4.0-5.3), and 174 patients experienced a CV disease event. All considered markers, except hs-TnI, were significantly (P <.001) associated with the outcome: abnormal echocardiogram (hazard ratio 2.40 [1.70-3.39]), albuminuria 2.01 (1.47-2.76), abnormal ECG (2.27 [1.66-3.08]), high NT-proBNP (>150 pg/mL) 3.05 (2.11-4.40), and hs-TnI 1.12 (0.79-1.59). After adjusting for clinical variables, all remained significantly associated with the end point. However, after adjusting for each other, only NT-proBNP >150 pg/mL remained significantly associated with the end point (2.07 [1.28-3.34], P <.001). Measured by C-statistics, model performance was highest with log 2 (NT-proBNP) (0.70 [0.65-0.75]) and similar to clinical variables alone (0.71 [0.67-0.76]). Combining all risk markers only resulted in a very limited increase in C-statistics (0.69 [0.64-0.74]). Conclusions: This study identified NT-proBNP over echocardiography, ECG, and albuminuria in risk prediction in patients with type 2 diabetes. The diagnostic yield in considering more than one risk marker was limited in this population.

OriginalsprogEngelsk
TidsskriftJournal of Diabetes
Vol/bind13
Udgave nummer9
Sider (fra-til)754-763
Antal sider10
ISSN1753-0393
DOI
StatusUdgivet - sep. 2021

    Forskningsområder

  • albuminuria, echocardiography, electrocardiography, plasma NT-proBNP, type 2 diabetes

ID: 64863487